Objective:
To evaluate the safety and efficacy of AAVB-081 gene therapy for Usher syndrome type 1B.
Key Findings:
- No drug-related serious adverse events or dose-limiting toxicities observed in initial follow-up.
- All 4 patients showed more than 1 line improvement in best-corrected visual acuity.
- 2 patients gained more than 3 lines in low-luminance visual acuity.
- Microperimetry fixation stability improved in 3 of the 4 patients.
- One participant demonstrated sustained benefit after one year.
Interpretation:
The preliminary results indicate that AAVB-081 may provide functional visual improvements with a favorable safety profile.
Limitations:
- Small sample size of 11 participants.
- Short follow-up duration for some patients.
Conclusion:
AAVB-081 shows promise as a potential treatment for Usher syndrome type 1B, but further follow-up is necessary to confirm long-term efficacy and safety.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.